Efruxifermin

Highest phase reached
Phase 3
www.ebi.ac.uk
Drug type
Protein
www.ebi.ac.uk

Listing at source
Listed
Highest phase reached
Phase 3
www.ebi.ac.uk

Drug type
Protein
www.ebi.ac.uk
Drug name
Efruxifermin
www.ebi.ac.uk

  • akr 001
  • AKR-001
  • amg 876
  • AMG 876
  • AMG-876
  • amg876
  • AMG876
  • efruxifermin
  • Efruxifermin
  • efruxifermin [INN]
  • EFRUXIFERMIN [USAN]
  • efruxifermin inn
  • efruxifermin usan
  • HUMAN IMMUNOGLOBULIN HEAVY CONSTANT .GAMMA.1 FC FRAGMENT HOMO SAPIENS IGHG1*01 .GAMMA.1-CHAIN (CH1DEL, HINGE(DEL(1-4),C5>M(1)), CH2, CH3)) (1-228)) FUSION PROTEIN WITH TRIS(TETRAGLYCYLSERYL) PEPTIDE LINKER (229-243) FUSION PROTEIN WITH HOMO SAPIENS FIBROBLAST GROWTH FACTOR 21 (FGF-21) VARIANT P(146) (L98>R(341),P171>G(414),A180>E(423)) MODIFIED, DIMER (7-7':10-10')-BISDISULFIDE
  • human immunoglobulin heavy constant gamma 1 fc fragment homo sapiens ighg1 01 gamma 1 chain ch1del hinge del 1 4 c5 m 1 ch2 ch3 1 228 fusion protein with tris tetraglycylseryl peptide linker 229 243 fusion protein with homo sapiens fibroblast growth factor 21 fgf 21 variant p 146 l98 r 341 p171 g 414 a180 e 423 modified dimer 7 7 10 10 bisdisulfide
  • IMMUNOGLOBULIN G (SYNTHETIC HUMAN CONSTANT DOMAIN FC FRAGMENT) FUSION PROTEIN WITH FIBROBLAST GROWTH FACTOR 21 (98-ARGININE,171-GLYCINE,180-GLUTAMIC ACID) (HUMAN MUTANT CLONE AMG876)
  • immunoglobulin g synthetic human constant domain fc fragment fusion protein with fibroblast growth factor 21 98 arginine 171 glycine 180 glutamic acid human mutant clone amg876
  • IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN C-REGION C-TERMINAL FRAGMENT) FUSION PROTEIN WITH PEPTIDE LINKER (GGGGS)3 FUSION PROTEIN WITH FIBROBLAST GROWTH FACTOR 21 (98-ARGININE,171-GLYCINE,180-GLUTAMIC ACID) (HUMAN), DIMER
  • immunoglobulin g1 human gamma 1 chain c region c terminal fragment fusion protein with peptide linker ggggs 3 fusion protein with fibroblast growth factor 21 98 arginine 171 glycine 180 glutamic acid human dimer

CAS registry numbers
  • 2375240-92-7
ChEMBL ID
CHEMBL4594389
www.ebi.ac.uk
FDA ingredient codes (UNII)
  • C1KR8TZ3NE

Patents
0
Designations
2
First in class
No
Fast track
No
Breakthrough designation
Yes
Orphan designation
No
Priority review
No
Orphan exclusivity
No
Accelerated approval
No

Drug name stem
ef-; -ermin

Investigated indications

  • Condition
    Non-alcoholic Fatty Liver Disease
    Highest recorded phase
    1
    Condition identifier
    EFO:0003095
    Subject identifier
    D065626

  • Condition identifier
    EFO_0000400
    Highest recorded phase
    1
  • Condition identifier
    EFO_0003095
    Highest recorded phase
    3
  • Condition identifier
    EFO_0006890
    Highest recorded phase
    3
  • Condition identifier
    EFO_1001249
    Highest recorded phase
    3
  • Condition identifier
    HP_0001394
    Highest recorded phase
    3
  • Condition identifier
    MONDO_0005148
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0007027
    Highest recorded phase
    3
  • Condition identifier
    MONDO_0013209
    Highest recorded phase
    3

Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Natural product
No

  • Component
    Sequence: monomer
    Type
    Protein
    Sequence
    MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSHPIPDSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIREDGTVGGAADQSPESLLQLKALKPGVIQILGVKTSRFLCQRPDGALYGSLHFDPEACSFRERLLEDGYNVYQSEAHGLPLHLPGNKSPHRDPAPRGPARFLPLPGLPPAPPEPPGILAPQPPDVGSSDPLSMVGGSQGRSPSYES
  • Component
    Disulfide bridges
    Sequence
    7-7' $ 10-10' $ 42-102 $ 42'-102' $ 148-206 $ 148'-206' $ 318-336 $ 318'-336'

Related records

Trials (8)

In development for (4)